Avidity Biosciences, Inc (RNAM) insider trading
Every open-market stock purchase and sale by Avidity Biosciences, Inc executives, directors, large shareholders and members of Congress, from SEC Form 4 filings. Sector: Other.
Insider activity at a glance
- No open-market insider trades in the last 12 months.
- No open-market insider buys on record.
Last 12 months: insiders bought $0 (0 buys) and sold $0 (0 sales).
Recent RNAM insider trades
| Date | Insider | Trade | Value |
|---|---|---|---|
| Feb 27, 2026 | Sarah Boyce (CEO) | Sold (not open market) | $9M |
| Feb 27, 2026 | John B Moriarty (C-suite exec) | Sold (not open market) | $7.1M |
| Feb 27, 2026 | Sarah Boyce (CEO) | Sold (not open market) | $6M |
| Feb 27, 2026 | Sarah Boyce (CEO) | Sold (not open market) | $5.2M |
| Feb 27, 2026 | Michael F MacLean (CFO) | Sold (not open market) | $3.3M |
| Feb 27, 2026 | Arthur A Levin (Insider) | Sold (not open market) | $3.2M |
| Feb 27, 2026 | Teresa McCarthy (Officer) | Sold (not open market) | $3.1M |
| Feb 27, 2026 | Sarah Boyce (CEO) | Sold (not open market) | $3M |
| Feb 27, 2026 | Charles Calderaro III (CTO) | Sold (not open market) | $2.5M |
| Feb 27, 2026 | Teresa McCarthy (Officer) | Sold (not open market) | $2.4M |
| Feb 27, 2026 | W. Michael Flanagan (C-suite exec) | Sold (not open market) | $2.2M |
| Feb 27, 2026 | Michael F MacLean (CFO) | Sold (not open market) | $2.1M |
| Feb 27, 2026 | Michael F MacLean (CFO) | Sold (not open market) | $1.9M |
| Feb 27, 2026 | Steven George Hughes (C-suite exec) | Sold (not open market) | $1.7M |
| Feb 27, 2026 | Arthur A Levin (Insider) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Eric Mosbrooker (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Kathleen P. Gallagher (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Michael F MacLean (CFO) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Teresa McCarthy (Officer) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Steven George Hughes (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Eric Mosbrooker (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | John B Moriarty (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | W. Michael Flanagan (C-suite exec) | Sold (not open market) | $1.6M |
| Feb 27, 2026 | Teresa McCarthy (Officer) | Sold (not open market) | $1.5M |
| Feb 27, 2026 | Sarah Boyce (CEO) | Sold (not open market) | $1.3M |
Who's trading RNAM
- Carsten Boess, Insider: other filings, last Feb 27, 2026
- Sarah Boyce, CEO: other filings, last Feb 27, 2026
- Charles Calderaro III, CTO: other filings, last Feb 27, 2026
- W. Michael Flanagan, C-suite exec: other filings, last Feb 27, 2026
- Kathleen P. Gallagher, C-suite exec: other filings, last Feb 27, 2026
- Noreen Henig, Insider: other filings, last Feb 27, 2026
- Steven George Hughes, C-suite exec: other filings, last Feb 27, 2026
- Edward M. Kaye MD, Insider: other filings, last Feb 27, 2026
- Jean Jinsun Kim, Insider: other filings, last Feb 27, 2026
- Arthur A Levin, Insider: other filings, last Feb 27, 2026
- Michael F MacLean, CFO: other filings, last Feb 27, 2026
- Teresa McCarthy, Officer: other filings, last Feb 27, 2026
- John B Moriarty, C-suite exec: other filings, last Feb 27, 2026
- Eric Mosbrooker, C-suite exec: other filings, last Feb 27, 2026
- Simona Skerjanec, Insider: other filings, last Feb 27, 2026
Get free alerts when an insider at Avidity Biosciences, Inc files a new trade →